GlassScriptPhysician profile
Michael Ray Royall
NPI 1356819320
$2,084.42
in general payments reported to CMS, 2019-2025
12 companies · $578 in 2025
The $578 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $181 · 2022: $154 · 2023: $239 · 2024: $932 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,749.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $520.08 | 2021-2025 | Prolate, Nalocet, Tanlor |
| Braeburn INC. | $434.92 | 2024-2025 | Brixadi |
| Indivior INC. | $399.32 | 2023-2025 | Sublocade |
| Orexo US, INC. | $386.87 | 2023-2025 | Zubsolv |
| Collegium Pharmaceutical, INC. | $139.35 | 2021-2024 | Belbuca |
| Alkermes, INC. | $83.51 | 2025 | Vivitrol |
| Uswm, LLC | $47.86 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $15.98 | 2022 | |
| Boston Scientific Corporation | $15.64 | 2021 | |
| Biodelivery Sciences International, INC. | $14.81 | 2021 | |
| Abbvie INC. | $13.31 | 2024 | |
| Pfizer INC. | $12.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Royall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.